Evommune Stifel 2026 Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Great. Good afternoon, everyone. I am Alex Thompson, Managing Director at Stifel. Very happy to have you with us today. We have Greg Moss, Chief Business and Legal Officer, and Jeegar Patel, Chief Scientific Officer. Maybe, Greg, if you want to give a quick overview of the company, and then we will get into a Q&A.
Sure. Evommune has always set out to be a meaningful player in the inflammatory disease space. To that end, we are moving forward a portfolio of programs targeting unique mechanisms and across a number of different modalities. At the moment, we are leading with EVO301, that is our IL-18 binding protein fusion protein. That is going to be entering a phase II-B study in atopic dermatitis in mid-next year. In addition, we are also doing a phase II-A study of that program in ulcerative colitis, and that is set to start at the beginning of next year. We also have EVO756, that is our MRGPRX2 antagonist. That program is solely being studied at the moment in migraine. Before that, we looked at it in subcutaneous diseases, designed studies to get to outcomes.
Unfortunately, didn't see what we wanted to see, but have bounced back and are looking forward to seeing that migraine data, and that will be available end of 2027. In addition, we are moving forward EVO646, that is a TLR7/8 small molecule that will be in a phase I study with a full biomarker plan next year, and that will have data towards the end of 2027. Last week, we announced that we have in-licensed a new program out of China. We will talk a little bit more about that later. That is a VAV1 molecular glue degrader, a really exciting program that is in its final stages of getting ready to start a phase I study. The phase I study will start in December or January. We plan to have data with that program and a full biomarker plan by the middle of next year.
Our entire hypothesis has been built around the idea that you need to manage a portfolio of programs, and we are always thinking about it from three separate and unique perspectives. The one is, does the biology support the hypothesis? Two, is there a very clear clinical and regulatory pathway? Three, can we study these in indications where not only is there a clear medical need, but is there a commercial opportunity? We think we have got a nice, well-rounded out portfolio that doesn't stop there. We continue to evaluate new opportunities in discovery. We have got a set of STAT6 degraders and inhibitors that we are looking at in discovery, and we look to advance those towards candidate selection next year. We are always being opportunistic as we consider business development and new research opportunities.
At the moment, funded through the end of 2029, and all those catalysts are well-supported by the existing resources.
Great. Yeah. Maybe let's kick things off with IL-18 and that story, because I think it's definitely an emerging target in atopic derm, and you generated some interesting data there. Maybe just set things off to start. Can you talk about where IL-18 sits in the inflammatory cascade and why is it interesting to an orthogonal target in atopic disease, or maybe more broadly?
Yeah, no, absolutely. I think, as we came to IL-18, it's been a target of interest for some time. We had an opportunity to in-license this molecule from a company called AprilBio, which had a unique IL-18 fusion protein. Took advantage of the IL-18 binding protein, which is the natural modulator of IL-18 biology. It's the natural brake that keeps the IL-18 signaling under control. It was fused to a serum albumin Fab that gave it the extended half-life and replacement value on a frequency that's amenable to some of the diseases that we're considering. The IL-18 biology is very interesting. Predominantly found from epithelial cells, dendritic cells, keratinocytes, can be produced in copious amounts in inflammatory diseases, especially in diseases like skin, atopic dermatitis. I think what makes it unique is that it's beyond just Th2 biology.
It's impacting Th2 biology significantly, but it's also impacting Th1, Th17, and Th22 biology as well. We find it very uniquely upstream of all the inflammatory cascades that can impact these inflammatory diseases in a more meaningful way. We look at it as it can expand the efficacy profile that we're seeing with some of the existing therapies that target one or two of those inflammatory cascades.
I think, yeah, I think one of the elements here that has been some focus on more recently is this idea that IL-18 and IL-37 signal through a shared receptor pair. I guess to what extent does IL-37, do we understand, interact with IL-18 binding protein, and is that a risk at all of your mechanism, that you actually are an IL-18 binding protein mimetic?
Yeah, no, absolutely. We're happy with the IL-18 binding protein approach. In our hands, certainly, we've done studies where we've looked at binding kinetics of IL-18 versus IL-1 beta and IL-37, because they're essentially the same family. There's actually no measurable or appreciable binding of 301 with those agents. What's reported in the literature is a bit kind of complex. There are some studies that have been done and reported by academic institutes highlighting IL-37 binding under what I would consider non-physiologic conditions to the IL-18 binding protein. We're talking micromolar or double-digit micromolar concentrations being administered in a rare complex formation, and then highlighting, again, non-quantitative amounts of interaction with the IL-18 binding protein. Those are conditions that people just not see physiologically. Just for reference, the ones that are out there talking about picomolar binding of IL-18 to IL-18 binding protein and double-digit micromolar binding, if any.
with the IL-37. IL-37 does have a role though. It is the- Sure anti-inflammatory cytokine that does go through the kind of the shared receptor.
So where the concern would be is if you're impacting that actual shared receptor biology, and we see no evidence of that.
Yeah. So maybe moving on to kind of the empirical data. Could you talk a little about what we've seen empirically in atopic dermatitis for IL-18 programs, including 301 so far?
Yeah. So, we were fortunate that we had very nice phase IIa data in atopic dermatitis. Nice EASI reductions that are in line with some of the other agents that are out there. What was most compelling about our data was that it was given with only two doses. So dosing only on day one and day 29, with a molecule that does sustain for a period of time. And we looked out at week 12, and we still had efficacy continue to improve even at that timeframe.
So I think that data was encouraging. We still have considerable opportunity as we go into phase IIb to increase our dose and also to increase our dose frequency, so we plan to do a full dose range-finding study. In that study, we also highlighted that we impacted significant levels of biomarkers, including Th2 cascade biomarkers with TARC, as well as markers of Th1, Th17, Th22. So we're capturing the biology that we saw pre-clinically now in the clinical studies, highlighting the broad impact of this mechanism.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
